Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the completion of the sale, the director owned 16,637 shares of the company’s stock, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP traded up $1.77 on Monday, reaching $58.33. 1,813,544 shares of the company’s stock were exchanged, compared to its average volume of 1,761,454. The company has a fifty day moving average of $53.08 and a 200-day moving average of $52.77. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $78.48. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The business had revenue of $10.18 million for the quarter. On average, research analysts predict that CRISPR Therapeutics AG will post -4.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Tuesday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $67.94.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new stake in CRISPR Therapeutics during the 4th quarter worth $25,706,000. Capital International Investors grew its holdings in shares of CRISPR Therapeutics by 4.3% during the fourth quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock worth $309,016,000 after purchasing an additional 243,487 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the first quarter valued at approximately $7,136,000. KBC Group NV increased its stake in shares of CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after buying an additional 113,997 shares during the period. Finally, Geode Capital Management LLC raised its holdings in CRISPR Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 2,249,223 shares of the company’s stock valued at $117,971,000 after buying an additional 108,053 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.